Clinical Practice Guidelines Example Implementation Guide - Chronic Kidney Disease
1.0.0 - ci-build
Clinical Practice Guidelines Example Implementation Guide - Chronic Kidney Disease
1.0.0 - ci-build
Clinical Practice Guidelines Example Implementation Guide - Chronic Kidney Disease, published by HL7 International - Clinical Decision Support WG. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/cpg-example-ckd/ and changes regularly. See the Directory of published versions
| Official URL: http://cqframework.org/cpg-example-ckd/PlanDefinition/cc-cpg-plan-ckd | Version: 1.0.0 | |||
| Active as of 2024-11-18 | Computable Name: ChronicKidneyDiseaseAmbulatory | |||
Usage:Clinical Focus: Chronic kidney disease (disorder) |
||||
Copyright/Legal: Copyright © Elsevier, and others. |
||||
Chronic Kidney Disease - Ambulatory
Generated Narrative: PlanDefinition cc-cpg-plan-ckd
CQF Knowledge capability: shareable
CQF Knowledge capability: computable
CQF Knowledge capability: publishable
CQF knowledge representation level: structured
url: PlanDefinition Chronic Kidney Disease - Ambulatory Plan Definition
version: 1.0.0
name: ChronicKidneyDiseaseAmbulatory
title: Chronic Kidney Disease - Ambulatory Plan Definition
type: Order Set
status: Active
experimental: true
date: 2024-11-18 18:20:09+0000
publisher: HL7 International - Clinical Decision Support WG
contact: HL7 International - Clinical Decision Support WG: http://www.hl7.org/Special/committees/dss/index.cfm
description:
Chronic Kidney Disease - Ambulatory
| Code | Value[x] |
| UsageContextType focus: Clinical Focus | Chronic kidney disease (disorder) |
jurisdiction: World
copyright:
Copyright © Elsevier, and others.
topic: Treatment
relatedArtifact
type: Justification
display: SYNOPSIS - Chronic Kidney Disease KEY POINTS Decline in function of the kidney characterized by at least 3 months of reduced GFR (less than 60 mL/minute/ 1.73 m²) or at least 3 months of structural or functional kidney damage Assessment of both GFR and albuminuria is necessary to diagnose chronic kidney disease and monitor disease progression GFR is most commonly estimated through measuring serum creatinine and the use of GFR estimating equations, either the Modification of Diet in Renal Disease Study equation or the Chronic Kidney Disease Epidemiology Collaboration equation Albuminuria is measured by urine albumin/creatinine ratio; greater than 30 mg/g indicates albuminuria Chronic kidney disease is commonly associated with hypertension, diabetes, and cardiovascular disease First line therapy includes ACE inhibitors and/or angiotensin II receptor blockers to reduce albuminuria and hypertension If left untreated, chronic kidney disease can progress to end-stage renal disease requiring dialysis or renal transplant Symptoms of end-stage renal disease (eg, pruritus, refractory electrolyte imbalances, metabolic acidosis, severe nausea, neurologic impairments) typically occur when GFR is 5 to 10 mL/minute/1.73 m² Carefully monitor electrolyte levels, hemoglobin, parathyroid hormone levels, and sodium bicarbonate levels to detect complications of chronic kidney disease, including cardiovascular disease, anemia, bone mineral disease, and metabolic acidosis URGENT ACTION Hyperkalemia may require urgent treatment in patients being treated for chronic kidney disease Urgent treatment consists of calcium chloride or calcium gluconate and regimens of sodium bicarbonate, glucose and insulin, or nebulized albuterol PITFALLS Early stages are often asymptomatic, causing chronic kidney disease to be untreated, leading to further progression of kidney damage and worse prognosis
citation:
Chronic Kidney Disease Clinical Overview. ClinicalKey. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75E10232E05352E3610A5325
library: Chronic Kidney Disease (CKD) risk screening logic
action
id
34387235title: Assessment Scales
groupingBehavior: Visual Group
action
id
34387238title: GFR Equations and Classification according to GFR Category
description: Nonorderable narrative
textEquivalent: GFR Equations and Classification according to GFR Category
documentation
type: Justification
display: Obtain serum creatinine for evaluation of GFR Estimate GFR from serum creatinine using 1 of 2 equations Chronic Kidney Disease Epidemiology Collaboration equation is preferred for reporting estimated GFR; more accurately represents true GFR, especially at GFR above 60 mL/minute/1.73 m² Modification of Diet in Renal Disease equation underestimates true GFR in patients with GFR above 60 mL/minute/1.73 m² Less accurate than the Chronic Kidney Disease Epidemiology Collaboration equation, though still widely used by many laboratories A GFR calculator (using the Chronic Kidney Disease Epidemiology Collaboration equation) is available from the National Kidney Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases Gold standard is to measure clearance of continuously infused inulin over 24 hours; however, this is neither practical nor cost effective If GFR is suspected to be inaccurate (eg, severe malnutrition, paraplegia, amputated extremity) testing involves a 24-hour urine collection GFR equations Chronic Kidney Disease Epidemiology Collaboration equation43 GFR (mL/minute/1.73 m²) = 141 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^-1.209 × 0.993^Age × 1.018 [if female] × 1.159 [if black] Scr = serum creatinine κ = 61.9 for females and 79.6 for males α = -0.329 for females and -0.411 for males Min indicates the minimum of Scr/κ or 1 Max indicates the maximum of Scr/κ or 1 Modification of Diet in Renal Disease equation GFR (mL/minute/1.73 m²) = 175 × (Scr)^-1.154 × (age)^-0.203 × 0.742 [if female] × 1.212 [if black] Classification according to GFR category G1: normal or high renal function GFR: greater than 90 mL/minute/1.73 m² G2: mildly decreased renal function GFR: 60 to 89 mL/minute/1.73 m² G3a: mildly to moderately decreased renal function GFR: 45 to 59 mL/minute/1.73 m² G3b: moderately to severely decreased renal function GFR: 30 to 44 mL/minute/1.73 m² G4: severely decreased renal function GFR: 15 to 29 mL/minute/1.73 m² G5: kidney failure GFR: less than 15 mL/minute/1.73 m² Combined GFR and albuminuria stage more accurately denotes the risk of progression of chronic kidney disease Verify chronicity of kidney disease If GFR less than 60 mL/minute/1.73 m² (GFR categories G3a-G5) or markers of kidney damage present, review history and previous measurements to determine duration of kidney disease If duration is greater than 3 months, chronic kidney disease is confirmed If duration is less than 3 months or unclear, chronic kidney disease is not confirmed; patients may have chronic kidney disease or acute kidney diseases (including acute kidney injury) or both, and tests should be repeated accordingly
citation:
Chronic Kidney Disease Clinical Overview. ClinicalKey. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75E80232E05352E3610A5325 requiredBehavior: Could
precheckBehavior: No
action
id
34387242title: General Care
groupingBehavior: Visual Group
action
id
34387243title: Patient Education
documentation
type: Justification
display: To improve long-term outcomes, lifestyle modifications to lower blood pressure to less than 140/90 mmHg should be made for those who are NOT at high risk for cardiovascular disease. The modifications include: Weight reduction, if indicated, and maintaining a healthy weight with body mass index (BMI) of 20 to 25 Reducing salt intake to 2 g per day of sodium, unless contraindicated Following a regular exercise program aiming for at least 30 minutes, 5 times a week, depending on cardiovascular tolerance Alcohol intake not more than 2 standard drinks per day for men and one standard drink per day for women
citation:
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2 (Suppl), 337-414. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75ED0232E05352E3610A5325 groupingBehavior: Visual Group
action
id
cc-cpg-activity-edu-hypertensiontitle: Patient education: Managing Your High Blood Pressure (Hypertension)
description: General Care
requiredBehavior: Could
precheckBehavior: No
definition: Patient education: Managing Your High Blood Pressure (Hypertension)
action
id
cc-cpg-activity-edu-renal-diettitle: Patient education: Renal diet
description: General Care
requiredBehavior: Could
precheckBehavior: No
definition: Patient education: Renal diet
action
id
34387251title: Medications
documentation
type: Justification
display: Drug therapy Select drug dosages based on GFR, and carefully monitor kidney function when prescribing nephrotoxic medications, as change in renal function alters drug metabolism Consult the Kidney Disease: Improving Global Outcomes Conference report for detailed dosing considerations and strategies for acute and chronic kidney disease Considerations for drugs commonly used by patients with chronic kidney disease ACE inhibitors Used to reduce blood pressure in the kidneys and reduce albuminurin Dual therapy with angiotensin receptor blockers is not recommended Use lower dose in patients with GFR less than 45 mL/minute/1.73 m²; do not routinely discontinue when GFR is less than 30 mL/minute/1.73 m² (remains nephroprotective) Follow serum potassium Angiotensin receptor blockers Used to reduce blood pressure in the kidneys and reduce albuminuria Dual therapy with ACE inhibitor is not recommended Use lower dose in patients with GFR less than 45 mL/minute/1.73 m²; do not routinely discontinue when GFR is less than 30 mL/minute/1.73 m² (remains nephroprotective) Follow serum potassium Calcium channel blockers Can be used in combination with ACE inhibitor or angiotensin receptor blocker to control hypertension 3 main classes Benzothiazepines (diltiazem) Preferred over dihydropyridines because of an antiproteinuric effect Phenylalkylamines (verapamil) Preferred over dihydropyridines because it has an antiproteinuric effect (no clear indication to discriminate use of benzothiazepines versus phenylalkylamines) Dihydropyridines (eg, nifedipine, amlodipine) Avoid prescribing calcium channel blockers without ACE inhibitor or angiotensin II receptor blocker, as sole use can lead to increased hyperfiltration and increased albuminuria Aldosterone receptor antagonists Spironolactone (nonselective) Carefully monitor for hyperkalemia Eplerenone (selective) Carefully monitor for hyperkalemia Antidiabetic agents Choice of therapy depends on type of diabetes, degree of glycemic control needed, and level of current kidney function Insulin May need dose reduction when GFR is less than 30 mL/minute/1.73 m² to avoid hypoglycemia as insulin is partly renally excreted No evidence-based guidelines or recommendations exist specifying which types of insulin to use or avoid depending on severity of chronic kidney disease Sulfonylureas First-generation sulfonylureas are contraindicated as they are affected by kidney function and increase risks of hypoglycemia Glipizide Second-generation sulfonylurea; preferred in patients with chronic kidney disease as it is metabolized primarily in the liver Biguanides Metformin Relatively contraindicated when GFR is less than 30 mL/minute/1.73 m² as there is a risk of lactic acidosis; consider risk-benefit if GFR is stable Diuretics Monitor for hyperkalemia and hypotension as diuretics can cause fluid imbalance resulting in electrolyte level disparities Thiazide Once daily recommended in patients with GFR of 30 mL/minute/1.73 m² or higher (categories G1-G3) Loop diuretics Once or twice daily recommended in patients with GFR less than 30 mL/minute/1.73 m² (categories G4-G5) Analgesics Acetaminophen is the analgesic recommended for short-term treatment of mild to moderate pain in patients with stages 3 to 5 chronic kidney disease; considered analgesic of choice for all patients with chronic kidney disease NSAIDs may be used for short-term therapy in patients up to stage 3 chronic kidney disease, with regular monitoring of renal function
citation:
Chronic Kidney Disease Clinical Overview. ClinicalKey. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75F50232E05352E3610A5325 groupingBehavior: Visual Group
action
id
34387256title: Antihypertensives
documentation
type: Justification
display: According to the Joint National Committee-8, establish a target blood pressure of 140/90 mmHg for patients with chronic kidney disease patients (expert opinion, grade E). According to the American College of Physicians, select either an ACE inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence) for patients with hypertension and stage 1 to 3 chronic kidney disease. After starting an ACE inhibitor, measure the short-term follow-up creatinine level and use the results to prompt further attention if it shows a rise of greater than 30%. Consider alternative causes of acute kidney injury as well as renal artery stenosis. Consider stopping the ACE inhibitor or angiotensin II receptor blocker medication.
citation:
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2 (Suppl), 337-414. Source
Qaseem A, Hopkins, RH Jr, et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;Source
James P, Oparil S, Carter B, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5), 507-520. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75FA0232E05352E3610A5325 groupingBehavior: Visual Group
action
id
34387257title: Enalapril Oral Tablet; 10 mg 1 time a day (dispense 30 tablet(s); 3 refills)
description: Formulary
requiredBehavior: Could
precheckBehavior: No
action
id
34387258title: Lisinopril 20 MG Oral Tablet; 1 tablet(s) 1 time a day (dispense 30 tablet(s); 3 refills)
description: Formulary
requiredBehavior: Could
precheckBehavior: No
action
id
34387261title: Antilipemics
groupingBehavior: Visual Group
action
id
34387264title: Simvastatin Oral Tablet; 5 mg 1 time a day (dispense 30 tablet(s); 3 refills)
description: Formulary
requiredBehavior: Could
precheckBehavior: No
action
id
34387265title: Diuretics
documentation
type: Justification
display: Consider using thiazides as diuretics in patients with early stages of chronic kidney disease. When GFR falls below 30-50 mL/minute/1.73 m2, thiazides as less effective. Give loop diuretics once or twice daily to patients with GFR less than 30 mL/minute/1.73 m2 (chronic kidney disease stages 4-5). Instruct patients to follow a low-sodium diet in addition to using diuretics to optimize volume status. Limit the use of potassium-sparing diuretics, such as triamterene and amiloride, in patients with chronic kidney disease because of the risk of hyperkalemia.
citation:
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2 (Suppl), 337-414. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B76030232E05352E3610A5325 groupingBehavior: Visual Group
action
id
34387266title: Furosemide Oral Tablet; 20 mg 1 time a day (dispense 30 tablet(s); 3 refills)
description: Formulary
requiredBehavior: Could
precheckBehavior: No
action
id
34387287title: Laboratory
groupingBehavior: Visual Group
action
id
34387288title: Chemistry
documentation
type: Justification
display: Electrolyte analysis Abnormalities of electrolytes and other solutes suggest disorders of renal tubular reabsorption and secretion Persistent abnormalities (lasting more than 3 months) in serum phosphate, potassium, parathyroid hormone, or calcium levels indicate decreased renal function associated with chronic kidney disease Potassium: greater than 5.5 mEq/L indicative of hyperkalemia or less than 4.0 mEq/L indicating hypokalemia Parathyroid hormone: results greater than 65 pg/mL are above the reference range Calcium: less than 8.4 mg/dL is below the reference range Phosphorus: less than 4.6 mg/dL is below the reference range Provide management of electrolyte disturbances Hyperkalemia and hypokalemia High (greater than 5.5 mEq/L) or low (less than 4 mEq/L) potassium levels are associated with increased mortality for patients with chronic kidney disease Patients with chronic kidney disease have a high risk of developing hyperkalemia, which can cause cardiac arrhythmias and sudden death 8% to 73% of patients with chronic kidney disease develop hyperkalemia compared to 2.6% to 3.2% in the general population Patients with hypokalemia have an 82% increased risk of reaching end-stage renal disease Hyperphosphatemia Target serum phosphorus is 2.7 to 4.6 mg/dL for categories G3 and G4, and 3.5 to 5.5 mg/dL for category G5 Reduce phosphorus intake and consult nephrologist for treatment with phosphate binders Guideline recommends monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in CKD G3a (Level of recommendation: 1C). In children, we suggest such monitoring beginning in CKD G2 (Level of recommendation: 2D). In patients with CKD G3a–G5D, it is reasonable to base the frequency of monitoring serum calcium, phosphate, and PTH on the presence and magnitude of abnormalities, and the rate of progression of CKD(Level of recommendation: Not Graded). Reasonable monitoring intervals would be: In CKD G3a–G3b: for serum calcium and phosphate, every 6–12 months; and for PTH, based on baseline level and CKD progression. In CKD G4: for serum calcium and phosphate, every 3–6 months; and for PTH, every 6–12 months. In CKD G5, including G5D: for serum calcium and phosphate, every 1–3 months; and for PTH, every 3–6 months. In CKD G4–G5D: for alkaline phosphatase activity, every 12 months, or more frequently in the presence of elevated PTH. In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities are identified, it is reasonable to increase the frequency of measurements to monitor for trends and treatment efficacy and side effects (Level of recommendation: Not Graded).
citation:
KDIGO Board. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1), 1-59. Source
Chronic Kidney Disease Clinical Overview. ClinicalKey. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B761A0232E05352E3610A5325 groupingBehavior: Visual Group
action
id
cc-cpg-activity-lab-metabolictitle: Lab: Comprehensive Metabolic Panel, Once
description: Laboratory
requiredBehavior: Could
precheckBehavior: No
definition: Lab: Comprehensive Metabolic Panel, Once
action
id
34387206title: Urine
documentation
type: Justification
display: For patients with a positive dipstick test (1+ or greater), perform confirmation of proteinuria by a quantitative measurement (protein-to-creatinine ratio or albumin-to-creatinine ratio) within 3 months. When screening adults at increased risk for chronic kidney disease, measure albumin in a spot urine sample using either of the following: Albumin-specific dipstick Albumin-to-creatinine ratio When monitoring proteinuria in adults with chronic kidney disease, measure the protein-to-creatinine ratio in spot urine samples using: Albumin-to-creatinine ratio Total protein-to-creatinine, only if albumin-to-creatinine ratio is more than 500-1000 mg/g (57-113 mg/mmol)
citation:
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter. 2013;Suppl 3, 1-150. Source
Documents
Url http://himss19.ordersetsmanager.com/evidenceviewer/#/7CBBBE9B75E10232E05352E3610A5325/7CBBBE9B75C80232E05352E3610A5325 groupingBehavior: Visual Group
action
id
cc-cpg-activity-lab-creatininetitle: Lab: Creatinine, Urine Random, Once
description: Laboratory
requiredBehavior: Could
precheckBehavior: No
definition: Lab: Creatinine, Urine Random, Once
action
id
34387217title: Radiology
groupingBehavior: Visual Group
action
id
cc-cpg-activity-ultrasound-renaltitle: Ultrasound
groupingBehavior: Visual Group
action
id
34387219title: Ultrasound, Renal; History: [add diagnosis, symptom(s)]; Question: [add reason for exam]
description: Imaging Studies
requiredBehavior: Could
precheckBehavior: No
definition: Ultrasound, Renal; History: [add diagnosis, symptom(s)]; Question: [add reason for exam]
action
id
cc-cpg-activity-referral-nephrologytitle: Referrals
groupingBehavior: Visual Group
action
id
34387224title: Referral: Nephrology; History: [add diagnosis, symptom(s)]; Question: [add reason for referral]
description: Referrals
requiredBehavior: Could
precheckBehavior: No
definition: Referral: Nephrology; History: [add diagnosis, symptom(s)]; Question: [add reason for referral]
action
id
cc-cpg-activity-referral-dietitiontitle: Referral: Dietitian; History: chronic kidney disease; Question: [add reason for referral]
description: Referrals
requiredBehavior: Could
precheckBehavior: No
definition: Referral: Dietitian; History: chronic kidney disease; Question: [add reason for referral]